Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose-and timedependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAILinduced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics.
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively in cancer cells in vitro and in vivo, with little or no effect on normal cells (Pitti et al., 1996; Keane et al., 1999; Walczak et al., 1999; Lawrence et al., 2001) . Therefore, TRAIL is one of the most promising new candidates for cancer therapeutics.
Death receptor 5 (DR5, also called TRAIL-R2, Apo2, TRICK2, or KILLER) is a member of the TNF receptor family and is a receptor for TRAIL (MacFarlane et al., 1997; Pan et al., 1997; Screaton et al., 1997; Sheridan et al., 1997; Walczak et al., 1997) . DR5 and DR4 (also called TRAIL-R1) mediate TRAIL-induced apoptosis through the formation of a death-inducing signaling complex containing the death receptor, adapter proteins, such as Fas-associated death domain (FADD), and certain initiator caspases, such as procaspase-8 (Ashkenazi and Dixit, 1998) or procaspase-10 ( Kischkel et al., 2001) . Consequently, procaspase-8 or -10 are activated by autoproteolytic processing, and the resulting active caspase-8 or -10 cleaves and activates downstream effector caspases, such as caspase-3, -6, and -7. On the other hand, Bid, a proapoptotic Bcl-2 family member, is also cleaved by caspase-8, and truncated Bid is an important mediator that connects the proapoptotic signal from the death receptor pathway to mitochondrial pathway. In addition, overexpression of DR5 (MacFarlane et al., 1997; Pan et al., 1997; Sheridan et al., 1997; Wu et al., 1997) and an agonistic monoclonal antibody specific for DR5 (Ichikawa et al., 2001; Ohtsuka et al., 2003) induce apoptosis in cancer cells in a ligand-independent manner.
In contrast, decoy receptors, DcR1, DcR2, and osteoprotegerin, which lack functional intracellular death domain, compete with DR4 and DR5 for TRAIL binding. DcR1 and DcR2 are expressed preferentially in many normal tissues but in only a few transformed cells Dixit, 1998, 1999) . Therefore, it is suggested that the expression of decoy receptors in normal tissues might protect normal cells from induction of apoptosis by TRAIL. On the other hand, some studies have reported that DR5 is expressed more strongly in cancer cells than in normal cells (Ichikawa et al., 2001; Koornstra et al., 2003) . Thus, expression of DR5 may contribute to the tumor-selective induction of apoptosis mediated by TRAIL. Accordingly, DR5 is considered to be a major death receptor on most tumor cells and an attractive target for cancer therapeutics.
To date, several potent inducers of DR5 have been identified. The p53 tumor-suppressor gene has been reported to transactivate DR5 gene expression (Wu et al., 1997 Takimoto and El-Deiry, 2000) . In addition, genotoxic reagents such as doxorubicin, etoposide and MMS, and g-radiation are also known to induce the expression of DR5 in a p53-dependent or -independent manner (Sheikh et al., 1998; Gibson et al., 2000; Gong and Almasan, 2000; Nagane et al., 2000; Wen et al., 2000) . The synthetic retinoid CD437 induces apoptosis together with the upregulation of DR5 in the lung and prostate carcinoma cells (Sun et al., 1999) . Moreover, the synthetic glucocorticoid dexamethasone and the cytokine interferon-g induce apoptosis and DR5 expression in cell lines with mutant p53 (Meng and El-Deiry, 2001 ). In addition, interferon-a (Shigeno et al., 2003) , sulindac sulfide (Huang et al., 2001; He et al., 2002b; Tang et al., 2002) , thapsigargin (He et al., 2002a) , and 2-methoxyestradiol (LaVallee et al., 2003) have been recently reported to be potent inducers of DR5.
Histone deacetylase inhibitors (HDACIs) are novel anticancer drugs that are potent inducers of growth arrest at both the G1 and G2/M phases (Yoshida and Beppu, 1988) and induce the differentiation and/or apoptotic cell death of various types of tumor cell lines (Marks et al., 2000) . Derivatives of butyric acid, SAHA, MS-275, and FK228, all of which are capable of acting as HDACIs, are currently undergoing clinical trials (Kramer et al., 2001) . HDACIs upregulate transcription of certain genes through the inhibition of HDAC and subsequent changes in chromatin structure (Davie, 1998; Kouzarides, 1999; Strahl and Allis, 2000) . For example, we previously reported that HDACIs (butyrate, TSA, and SAHA) induce the p21/WAF1 expression through Sp1 sites of the promoter in a p53-independent manner Sowa et al., 1997; Huang et al., 2000) . Recently, we have reported that HDACIs induce Gadd45 in a p53-independent manner and both Oct-1 and NF-Y participate in the HDACI-induced activation of the gadd45 promoter (Hirose et al., 2003) . We have also reported that the p15
INK4b gene, a member of the INK4 gene family, is also induced through its promoter in HaCaT cells (Hitomi et al., 2003) .
In this study, we show that HDACIs such as TSA, sodium butyrate, and SAHA upregulate DR5 expression in various human malignant tumor cells including p53-null mutant cells. This results in the synergistic enhancement of exogenous soluble recombinant human TRAIL-induced apoptosis in malignant tumor cells but not in normal peripheral blood mononuclear cells. Furthermore, we demonstrate that combined treatment with HDACIs and TRAIL induces apoptosis mediated by the sequential cleavage of Bid, and the activation of caspase-8, -10, -9, and -3, depending on TRAIL-death receptor interaction.
Results

HDACIs increase the expression of DR5
We first investigated effects of HDACIs on the expressions of death receptor-related genes using an RNase protection assay. As shown in Figure 1a , both TSA and sodium butyrate significantly upregulated DR5 mRNA in Jurkat human T-cell acute lymphoblastic leukemia cells carrying inactivated p53 with a point mutation. DR4 and TRAIL expressions were not altered markedly. Fas expression decreased, and caspase-8 also decreased slightly. DcR1 expression was not detected. We next carried out a Northern blot analysis to confirm the upregulation of DR5 mRNA by TSA (Figure 1b and c). TSA treatments increased DR5 mRNA in a dose-and time-dependent manner. As shown in Figure  1d -g, we also demonstrated HDACIs, TSA, sodium butyrate, and SAHA increased DR5 expression on the protein level in a dose-and time-dependent manner by Western blot analysis. These two band patterns of DR5 protein are consistent with the results of previous report , and we confirmed that these two bands were detected by immunoblot analysis reprobed with another specific goat anti-DR5 antibody (Calbiochem, La Jolla, CA, USA) reacting to a different epitope (data not shown).
HDACIs increase DR5 promoter activity
We next investigated the effect of HDACIs on DR5 promoter activity. We used the DR5 promoter-luciferase reporter plasmid described previously (Yoshida et al., 2001) for the transient luciferase assay. As shown in Figure 2 , all of the HDACIs we tested, such as TSA, sodium butyrate, and SAHA, increased DR5 promoter activity significantly. These results indicate that HDACIs stimulate the DR5 promoter activity in Jurkat cells. It is worth mentioning that the DR5 promoter plasmid we used does not contain an intronic p53-binding site. Furthermore, Jurkat cells harbor inactivated p53 with a point mutation. Therefore, HDACIs upregulate DR5 through a p53-independent mechanism.
HDACIs sensitize TRAIL-induced apoptosis in Jurkat cells in a synergistic manner
We hypothesized that HDACIs might enhance exogenous TRAIL-induced apoptosis due to their ability to increase DR5 expression. At first, we investigated a minimal concentration of TSA (Figure 3a but free TRAIL (Apo2L/TRAIL.0) in this study, because His-tagged TRAIL has been shown to be more toxic to human normal hepatocytes than non-Histagged TRAIL (Jo et al., 2000; Lawrence et al., 2001 ). These results indicated that Jurkat cells were relatively tolerant to non-His-tagged free TRAIL, for example, 50 ng/ml of TRAIL for 24 h induced only 12% apoptosis in Jurkat cells. We next tested a combined treatment with TSA and TRAIL ( Figure 3c ). The results indicated that TSA strongly sensitized exogenous recombinant TRAIL-induced apoptosis in a synergistic manner. For example, the concurrent treatment with TSA at 0.5 mM and TRAIL at 50 ng/ml induced 58% apoptosis approximately. On the other hand, TNF-a also has been known to induce apoptosis through an extrinsic pathway similar to TRAIL. However, TSA did not synergistically enhance apoptosis caused by TNF-a (Figure 3d ). This observation implies importance of DR5 induction for synergistic enhancement of TRAILinduced apoptosis by TSA.
Sodium butyrate and SAHA also sensitize TRAIL-induced apoptosis in Jurkat cells Next, we confirmed that not only TSA but also other HDACIs sensitized TRAIL-induced apoptosis ( Figure  4a and c). Indeed, both sodium butyrate and SAHA markedly sensitized apoptosis by TRAIL. These concentrations of HDACIs that sensitized apoptosis by TRAIL-induced DR5 protein, as shown in Figure 1f and g. These results indicated that all the HDACIs we tested induced DR5 and sensitized TRAIL-induced apoptosis. In addition, not only TSA but also other HDACIs, sodium butyrate, and SAHA did not synergistically enhance TNF-a-induced apoptosis (Figure 4b and d).
Combined treatment with HDACIs and TRAIL induces synergistic apoptosis coupled with Bid cleavage and activation of caspase-8, -10, -9, and -3
In order to confirm the activation of apoptotic signals when combined treatment with HDACIs and TRAIL synergistically enhances apoptosis, we performed a Western blot analysis of DR5, Bid, caspase-8, -10, -9, and -3 when both TSA and TRAIL or each alone were given at a suboptimal concentration ( Figure 5 ). DR5 upregulation was also observed when TSA was given with TRAIL. TSA treatment gradually induced DR5 upregulation from 0.05 to 0.5 mM and the upregulation saturated from 0.5 to 2 mM ( Figure 5 ), which was consistent with the concentrations of the apoptotic enhancement (Figure 3c ). It was also clearly shown that only combined treatment with HDACIs and TRAIL induced Bid cleavage and activation of caspase-8, -10, -9, and -3. These results were consistent with the correlation between the HDACI-induced DR5 upregulation and the sensitization of apoptosis induced by TRAIL.
DR5/Fc chimera protein and caspase inhibitors block apoptosis enhanced by the combination of HDACIs and TRAIL
In order to confirm that the enhancement of apoptosis by HDACIs and TRAIL is mediated through interactions between TRAIL and its receptors, we employed human recombinant DR5/Fc chimera protein to block TRAIL from combining with its receptors. As shown in Figure 6 , human recombinant DR5/Fc chimera protein efficiently blocked apoptosis caused by the combined treatment with TSA and TRAIL. These results indicated that the synergistic enhancement of apoptosis caused by Figure 2 HDACIs increase DR5 promoter activity. Jurkat cells were transiently transfected with the DR5 promoter-luciferase reporter plasmids (pDR5/SacI) or vacant vector pGVB2. From 24 h after transfection, Jurkat cells were treated with or without TSA (1 mM), sodium butyrate (10 mM), or SAHA (10 mM) for 24 h, and then harvested and assayed as described in Materials and methods. Data represent means of triplicate experiments (bars, S.D.). *Po0.02. SB: sodium butyrate; CT: treatment with solvents; EtOH for TSA; water for sodium butyrate; DMSO for SAHA cotreatment with HDACIs and TRAIL was mediated not by nonspecific toxicity, but through specific interactions between TRAIL and its receptors. We also demonstrated that zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently interrupted apoptosis induced by treatment with HDACIs and TRAIL. These observations were consistent with the characteristic features of TRAIL-induced apoptosis, well documented previously, which were mediated by caspase-8 (Ashkenazi and Dixit, 1998) or caspase-10 directly downstream of the TRAIL receptors. In addition, caspase-1, -3, and -9 inhibitors could partially attenuate apoptosis induced by HDACIs and TRAIL. These caspases have also been reported to be involved in TRAIL-induced apoptosis (Mariani et al., 1997; Muhlenbeck et al., 1998; Walczak et al., 2000) . 
TSA does not significantly induce DR5 protein and HDACIs do not enhance TRAIL-induced apoptosis in normal peripheral blood mononuclear cells
If HDACIs also markedly induce DR5 in normal cells, it is possible that HDACIs enhance not only antitumor effect but also the toxicity against normal cells by TRAIL. Therefore, we studied whether TSA upregulates DR5 expression in peripheral blood mononuclear cells or not (Figure 8a ). Peripheral blood mononuclear cells express very low-level DR5 compared with Jurkat cells and TSA did not increase DR5 protein significantly. Furthermore, we demonstrated that HDACIs such as TSA, sodium butyrate, and SAHA did not enhance TRAIL-induced apoptosis in peripheral blood mononuclear cells as shown in Figure 8b . HDACIs induce DR5 and sensitize TRAIL-induced apoptosis S Nakata et al
Discussion
In cancer therapeutics, it is very important to induce apoptosis specifically in malignant tumor cells but not in normal cells. In this regard, TRAIL is an attractive candidate for cancer treatment due to its ability to induce apoptosis selectively in cancer cells. The agonistic anti-DR5 monoclonal antibody that induces apoptosis in cancer cells is also promising for cancer treatment (Ichikawa et al., 2001; Ohtsuka et al., 2003) . These strategies are based on the expression of the death receptors on cancer cells. Overexpression of DR5 in TRAIL-resistant cancer cells restored TRAIL sensitivity (Yeh et al., 1998; Kuang et al., 2000; Mitsiades et al., 2001) . Recently, it has been reported that DR5 expression in a number of Jurkat subclones was highly correlated with sensitivity to TRAIL (Jang et al., 2003) . This evidence can provide a strategy to induce DR5 expression in order to enhance the susceptibility of cancer cells to TRAIL or the anti-DR5 monoclonal antibody.
In this present study, we showed that HDACIs upregulated DR5 mRNA and protein in a dose-and time-dependent manner (Figure 1) . The fact that all HDACIs we tested, such as TSA, sodium butyrate, and SAHA, induce DR5 suggests that DR5 is induced by histone deacetylase inhibition. Furthermore, we demonstrated that HDACIs activated DR5 promoter (Figure 2) . p53 transactivates the DR5 gene through an intronic p53-binding site (Wu et al., 1997 Takimoto and El-Deiry, 2000) . We used the 5 0 -flanking region of the DR5 gene from a human genomic library without a p53-binding site for the luciferase reporter assay. In addition, Jurkat cells harbor inactivated p53 with a point mutation. Thus, our results indicate that HDACIs activate DR5 gene transcription through its promoter activation in a p53-independent manner.
We next demonstrated that HDACIs sensitized TRAIL-induced apoptosis synergistically associated with the upregulation of DR5. Combined treatment with HDACIs and TRAIL induced apoptosis at suboptimal concentrations in which each agent alone induced only a small amount of apoptosis in Jurkat cells. Whereas some previous reports showed that HDACIs sensitize TRAILinduced apoptosis (Inoue et al., 2002; Rosato et al., 2003; Zhang et al., 2003; Neuzil et al., 2004) , the underlying mechanisms have not been elucidated. We first showed several pieces of evidence suggesting that the enhancement of apoptosis is caused by DR5 upregulated by HDACIs as follows: (1) Other members of the death receptor family are not induced by HDACIs. It is especially important that DR4 is not induced by HDACIs (Figure 1a) . Furthermore, it has been reported that DR4 is not expressed in Jurkat cells Jang et al., 2003) . (2) Bid and caspase-8 and -10 are important direct downstream mediators of DR5. These mediators were activated only when both HDACIs and TRAIL were given at suboptimal concentrations. (3) The concentrations at which HDACIs enhanced TRAILinduced apoptosis, cleaved Bid, and activated caspase-8 and -10 well correspond with those at which HDACIs upregulated DR5 protein (Figure 3c and 5) . (4) DR5/Fc chimera protein efficiently blocked apoptosis induced by combined treatment with HDACIs and TRAIL, which indicated TRAIL indeed interacted with its receptors (Figure 6 ). 5, Caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by combined treatment with HDACIs and TRAIL ( Figure 6 ). (6) HDACIs did not synergistically enhance apoptosis caused by TNF-a, which induces apoptosis through an extrinsic pathway similar to TRAIL (Figure 3d and 4b, d) .
The involvement of Bid and caspase-8 and -10 is consistent with the characteristic features of TRAILinduced apoptotic signals well documented previously (LeBlanc and Ashkenazi, 2003) . Thus, these results suggest that HDACIs sensitize apoptosis induced mainly by TRAIL. This raises the possibility that HDACIs can reduce the minimal effective dose or side effects of TRAIL. Furthermore, we demonstrated that TSA did not significantly upregulate DR5 expression in normal peripheral blood mononuclear cells and HDACIs did not enhance apoptosis induced by TRAIL in these cells. These results suggest that combination of HDACIs and TRAIL might be useful for cancer therapeutics.
In summary, we have shown that HDACIs activate the DR5 gene through p53-independent regulation. Furthermore, HDACIs can synergistically augment TRAIL-induced apoptosis selectively in human malignant tumor cells. Our results suggest that combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics.
Materials and methods
Reagents
TSA (Wako, Osaka, Japan), sodium butyrate (Wako), and SAHA (Biomol, Plymouth Meeting, PA, USA) were dissolved in ethanol, water, and DMSO, respectively. Soluble recombinant human TRAIL/Apo2L was purchased from PeproTech (London, UK). Human recombinant DR5 (TRAIL-R2)/Fc chimera protein, and the caspase inhibitors zVAD-fmk, zWEHD-fmk, zDEVD-fmk, zIETD-fmk, zLEHD-fmk, and zAEVD-fmk were purchased from R&D Systems (Minneapolis, MN, USA). Human recombinant TNF-a was purchased from SIGMA (St Louis, MO, USA).
Cell lines and cell culture
Jurkat human T-cell acute lymphoblastic leukemia cells, HL-60 acute myeloid leukemia cells, K-562 chronic myeloid leukemia cells, and U-937 histiocytic lymphoma cells were maintained in RPMI1640 medium with 10% fetal bovine serum. SW480 colon cancer cells and MCF7 breast cancer cells were maintained in DMEM medium with 10% fetal bovine serum. All of cell lines were incubated at 371C in a humidified atmosphere of 5% CO 2 . Normal peripheral blood mononuclear cells were isolated using a Ficoll-Paque PLUS (Amersham Biosciences, Piscataway, NJ, USA) density gradient according Figure 6 DR5/Fc chimera and caspase inhibitors block apoptosis enhanced by the combination of HDACIs and TRAIL. Jurkat cells were treated with TSA (0.5 mM) and/or TRAIL (50 ng/ml) for 24 h with or without various inhibitors. DR5/Fc, treated with DR5/Fc chimera protein (1 mg/ml); VAD, treated with zVAD-fmk pancaspase inhibitor; C-1, treated with zWEHD-fmk caspase-1 inhibitor; C-3, with zDEVD-fmk caspase-3 inhibitor; C-8, with zIETD-fmk caspase-8 inhibitor; C-10, with zAEVD-fmk caspase-10 inhibitor; C-8 þ 10, cotreated with zIETD-fmk caspase-8 inhibitor and zAEVD-fmk caspase-10 inhibitor; C-9, with zLEHD-fmk caspase-9 inhibitor. All of the caspase inhibitors were given at 10 mM. Sub-G1 populations (apoptotic cells) were detected using flow cytometry analysis as described in Materials and methods. We confirmed that treatment with DMSO at a 0.1-0.2% dilution did not cause cellular toxicity. Data represent means of triplicate experiments (bars, S.D.) to the manufacturer's instructions, and maintained for 24 h in X-VIVO 20 (Cambrex, Walkersville, MD, USA) serum-free medium with 0.2% BSA (SIGMA, St Louis, MO, USA) at 371C in a humidified atmosphere of 5% CO 2 .
Northern blot analysis and RNase protection assay Total RNA was isolated using a Sepasol RNA isolation kit (Nacalai Tesque Inc., Kyoto, Japan). A full length of DR5 cDNA was used as a probe for the Northern blot analysis. 32 Plabeled probe was hybridized in PerfectHyb (TOYOBO, Osaka, Japan). Wash conditions were according to the manufacturer's instructions. The mRNA level was determined using X-Ray Films (KODAK, Chalon-sur-Saone, France). The RNase protection assay was performed using an RPA III kit (Ambion, Inc., Austin, TX, USA). According to the manufacturer's instructions, labeled RNA probes were generated with the hAPO3d (death receptors and death ligands) template sets (PharMingen), including a ribosomal protein L32 template and a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) template as internal controls, labeled with [a-32 P]UTP using T7 RNA polymerase (MAXI script, Ambion). The labeled RNA probes were hybridized with 10 mg of total RNA from Jurkat cells. Samples were digested with RNase to remove nonhybridized RNA. The remaining probes were resolved on 5% urea-polyacrylamide gels.
Western blot analysis
Cells were washed once with phosphate-buffered saline and lysed with 100-150 ml of sodium dodecyl sulfate (SDS) buffer (50 mM Tris-HCl, pH 7.5, 1% SDS, 0.5 mM PMSF, 2 mg/ml Aprotinin, 2 mg/ml Leupeptin, and 1 mM DTT). The whole-cell extracts were electrophoresed with 10-12.5% SDS-polyacry- lamide gels and transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA). Rabbit polyclonal anti-DR5 antibody (Cayman Chemical, Ann Arbor, MI, USA), mouse monoclonal anti-Bid, anti-caspase-8, -9, -10 antibodies (MBL, Nagoya, Japan), and mouse monoclonal anti-procaspase-3 antibody (Immunotech, Marseille, France) were used as the primary antibodies. The signal was then developed with the enhanced chemiluminescence system (ECL, Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Transfection and luciferase assay
As described previously (Yoshida et al., 2001) , digested SacINcoI fragment from the DR5 promoter region of the genomic DNA was subcloned into the SacI-NcoI site of the pGVB2 luciferase assay vector (Toyo Ink, Tokyo, Japan) to produce pDR5/SacI. pDR5/SacI and vacant vector plasmids (1.0 mg) were transfected into Jurkat cells (1 Â 10 6 cells) using the DEAE-dextran method (CellPhect, Amersham Pharmacia Biotech, Piscataway, NJ, USA). After 24 h, the cells were treated with or without HDACIs for 24 h, and then cells were harvested. Then, luciferase assays were performed using luciferase assay reagents (Promega, Madison, WI, USA) and a luminometer. Each experiment was repeated at least three times. Data were normalized by protein concentration using a Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Data were analysed using a Student's t-test and differences were considered significant from controls when Po0.05. HDACIs induce DR5 and sensitize TRAIL-induced apoptosis S Nakata et al
Detection of apoptosis
DNA fragmentation was quantified by the percentage of cells with hypodiploid DNA (sub-G1). In brief, cells were fixed with 70% ethanol, treated with Ribonuclease A (SIGMA Chemical Co, St Louis, MO, USA), and the nuclei were stained with propidium iodide (SIGMA). The DNA content was measured using a FACSCalibur flow cytometer and Cell Quest software (Becton Dickinson, Mountain View, CA, USA). For all assays, 10,000 cells were counted.
Abbreviations DR5, death receptor 5; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TNF, tumor necrosis factor; HDACIs, histone deacetylase inhibitors; TSA, trichostatin A; SAHA, suberoylanilide hydroxamic acid; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
